☆ 4.2 Article

Exhaled Nitric Oxide in Pregnant Healthy and Asthmatic Women

JOURNAL OF ASTHMA (2009)

Journal

JOURNAL OF ASTHMA

Volume 46, Issue 8, Pages 786-791

Publisher

INFORMA HEALTHCARE

DOI: 10.3109/02770900903090004

Keywords

nitric oxide; FENO; pregnancy; asthmatics; NIOX MINO; asthma control

Funding

Hungarian Scientific Research Foundation [OTKA 68808]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Abstract

Background. Measurement of fractioned exhaled nitric oxide (FENO) is useful for monitoring airway inflammation in asthma. Asthma is one of the most common diseases complicating pregnancy, and FENO may be helpful for monitoring asthma in pregnancy. However, some physiological alterations of FENO may be expected during healthy pregnancy due to vascular nitric oxide production. Until now no study assessed the level of FENO in asthmatic pregnant patients. Objective. We aimed to assess the possible use and reproducibility of FENO measurements in pregnant asthmatic women. We compared FENO concentrations between four groups of subjects: healthy nonpregnant and pregnant females and asthmatic nonpregnant and pregnant patients. We also investigated the relationship between FENO values and the level of asthma control in pregnant asthmatic patients. Methods. A total of 102 female subjects (35 healthy nonpregnant and 27 healthy pregnant females; 20 nonpregnant and 20 pregnant asthmatic women) were included in this cross-sectional study. Two FENO measurements were performed in each subject using an electrochemical sensor based device (NIOX MINO, Aerocrine, Solna, Sweden). Data are given as median with range. Results. The repeatability of FENO measurement was similar in pregnant and nonpregnant subjects. FENO levels did not differ significantly between healthy pregnant versus nonpregnant subjects (16.0 [8, 31] vs. 16.0 [9, 35] ppb). FENO levels were significantly increased in asthmatic women compared to healthy females (nonpregnant asthmatics: 38 [9, 54] ppb, p < 0.001 vs. healthy nonpregnant; pregnant asthmatic patients: 28 [10, 56] ppb; p < 0.05 vs. healthy pregnant). Conclusions. FENO level is not influenced by healthy pregnancy. In pregnant asthmatic patients FENO level is elevated compared to healthy pregnant subjects and correlates with the level of asthma control. Further studies are required to assess the use of FENO measurement to monitor asthma in this patient group.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Update on the Role of FeNO in Asthma Management

Neveda Murugesan, Damini Saxena, Arundhati Dileep, Muhammad Adrish, Nicola A. Hanania

Summary: Asthma is a heterogeneous disorder with different phenotypes and endotypes. About 10% of individuals have severe asthma, which increases the risk of morbidity and mortality. Fractional exhaled nitric oxide (FeNO) is a cost-effective biomarker used to detect type 2 airway inflammation. FeNO can be measured as an adjunct to diagnostic evaluation and for monitoring airway inflammation in individuals with suspected asthma. However, FeNO may not be a good biomarker to rule out asthma due to its lower sensitivity. It can also be used to predict response to inhaled corticosteroids, adherence, and determine biologic therapy. Higher levels of FeNO are associated with lower lung function and increased risk of future asthma exacerbations, and its predictive value improves when combined with other standard measurements of asthma assessment.

DIAGNOSTICS (2023)